Navigation Links
IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
Date:5/22/2012

NEW YORK, May 22, 2012 /PRNewswire/ --  IntelliCell BioSciences, Inc. ("Company") (OTCQB: SVFC.PK)  announced today that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine (ICERM)  at the University of Florida.  A portion of the collaborative work will be to explore the physiological characteristics of the adult autologous vascular cells that are also referred to as stromal vascular fraction cells which form the basis of the IntelliCell product.  The company also intends to explore combination therapies with patent pending bio-engineered products under development.  The Company believes that the IntelliCell product is an efficient cellular delivery platform for a variety of therapeutic applications and will look to partner with technology developers.

Said Jon Dobson, Ph.D., Professor of biomedical engineering and biomaterials at the University of Florida, "We are pleased to be working with IntelliCell. Their technology is innovative and appears to hold promise for future regenerative medicine applications.  The use of adult autologous (your own) stem cells to repair and regenerate tissues are of great interest to personalized medicine researchers." Professor Dobson is a leading researcher in bionanotechnology and nanomedicine applications and apart from regenerative medicine, his work also spans across fields as diverse as gene therapy, stem cell therapy and tumor targeting. He is also the Director of the newly formed Institute for Cell Engineering and Regenerative Medicine at the University of Florida.

Dr. Steven Victor, CEO of IntelliCell, added "This is a very exciting time for regenerative medicine companies.  We are looking forward to long and productive research collaboration with the University of Florida and Professor Dobson.  IntelliCell believes that important contributions for better medicine will result from research collaborations with our university research colleagues."   Robert Sexauer, Executive Vice President, ICBS Research, stated that "we would like to take a thought leadership position by working closely with those at the vanguard of regenerative medicine development."

About IntelliCell BioSciences

IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using adult autologous vascular cells (SVC's) derived from the blood vessels in the adult adipose tissue. IntelliCell Biosciences has developed its own patent pending protocol to separate adult autologous vascular cells from adipose tissue without the use of enzymes. IntelliCell will also be seeking to develop technology licensing agreements with technology developers, universities, and international business entities.

About University of Florida

The University of Florida is one of the nation's largest public universities.  A member of the Association of American Universities, UF receives more than $619 million annually in sponsored research funding.  Through its research and other activities, UF contributes more than $8.76 billion a year to Florida's economy and has a total employment impact of more than 100,000 jobs statewide. www.ufl.edu.University of Florida Research: Working for Florida.

Forward-Looking Statements

Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contacts:

IntelliCell BioSciences, Inc.
Rubenstein Investor Relations
Contact: Tim Clemensen
Email Contact: TClemensen@rubensteinir.com
(212) 843-9337  

University of Florida
College of Engineering
Helen Goh
Email Contact: hgoh@eng.ufl.edu


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
2. IntelliCell BioSciences Expands Management Team
3. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
4. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
5. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
6. Milestone Biosciences, LLC Further Strengthens Executive Management Team
7. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
8. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
9. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
10. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
11. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Village, CA (PRWEB) , ... August 17, 2017 ... ... technology for cancer research and personalized medicine, today announced the launch of a ... Kansas City, Missouri. The study’s goal is to evaluate the potential for early ...
(Date:8/16/2017)... ... August 16, 2017 , ... Today, 3Bar Biologics Inc ... $2M in funding from an impressive group of investors, including Rev1 Ventures, Maumee ... With this investment, 3Bar is broadening availability of its groundbreaking offering that uses ...
(Date:8/15/2017)... Charlotte, NC (PRWEB) , ... August 15, 2017 , ... ... in 2017, celebrating 10 years of successes helping medical technology companies and inventors develop ... company to a renowned full-service national engineering firm with a portfolio of clients in ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology:
(Date:3/30/2017)... The research team of The Hong Kong Polytechnic University (PolyU) ... ground breaking 3D fingerprint minutiae recovery and matching technology, pushing contactless ... use in identification, crime investigation, immigration control, security of access and ... ... A research team led by Dr Ajay Kumar ...
(Date:3/28/2017)... 2017 The report "Video Surveillance ... Servers, Storage Devices), Software (Video Analytics, VMS), and Service ... Forecast to 2022", published by MarketsandMarkets, the market was ... projected to reach USD 75.64 Billion by 2022, at ... base year considered for the study is 2016 and ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
Breaking Biology News(10 mins):